Page last updated: 2024-09-05

lenalidomide and Nervous System Disorders

lenalidomide has been researched along with Nervous System Disorders in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	4 (66.67)	24.3611
2020's	1 (16.67)	2.80

Authors

Authors	Studies
Ahmed, Z; Anwer, F; Ashraf, A; Ehsan, H; Faisal, MS; Khakwani, M; Khan, A; Mushtaq, K; Rafae, A; Rehan, T; Shah, Z; Wahab, A	1
Bartlett, NL; Blum, KA; Cheson, BD; Johnson, J; Jung, SH; LaCasce, A; Morrison, VA; Pitcher, BN	1
Alexanian, R; Delasalle, K; Giralt, S; Wang, M	1
Giraldo, P; Lecumberri, R; Nistal, S; Tomás, JF	1
Fabiano, AJ; Fenstermaker, RA; Qiu, J; Rigual, D	1
Anderson, KC; Balinski, K; Catley, LP; Chauhan, D; Davies, F; Deocampo, R; Doss, D; Freeman, A; Hideshima, T; Kelly, K; LeBlanc, R; McKenney, M; Mechlowicz, J; Mitsiades, C; Rich, R; Richardson, PG; Ryoo, JJ; Schlossman, RL; Weller, E; Zeldis, J	1

Trials

2 trial(s) available for lenalidomide and Nervous System Disorders

Article	Year
Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leukemia & lymphoma, 2015, Volume: 56, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Lymphopenia; Male; Middle Aged; Nausea; Nervous System Diseases; Recurrence; Remission Induction; Thalidomide; Treatment Outcome	2015
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 2002, Nov-01, Volume: 100, Issue:9 Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Combined Modality Therapy; Constipation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Myeloma Proteins; Nervous System Diseases; Neutropenia; Peripheral Blood Stem Cell Transplantation; Remission Induction; Safety; Salvage Therapy; Thalidomide; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome	2002

Article

Year

Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501).

Leukemia & lymphoma, 2015, Volume: 56, Issue:4

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Lymphopenia; Male; Middle Aged; Nausea; Nervous System Diseases; Recurrence; Remission Induction; Thalidomide; Treatment Outcome

2015

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Blood, 2002, Nov-01, Volume: 100, Issue:9

Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Combined Modality Therapy; Constipation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Myeloma Proteins; Nervous System Diseases; Neutropenia; Peripheral Blood Stem Cell Transplantation; Remission Induction; Safety; Salvage Therapy; Thalidomide; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome

2002

Other Studies

4 other study(ies) available for lenalidomide and Nervous System Disorders

Article	Year
Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation. Expert review of hematology, 2020, Volume: 13, Issue:12 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Doxorubicin; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm, Residual; Nervous System Diseases; Progression-Free Survival; Proteasome Inhibitors; Thalidomide; Transplantation, Autologous; Vincristine	2020
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD). Hematology (Amsterdam, Netherlands), 2010, Volume: 15, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Female; Hematologic Diseases; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Nervous System Diseases; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Retrospective Studies; Thalidomide; Time Factors; Transplantation, Autologous	2010
POEMS syndrome with severe neurological damage clinically recovered with lenalidomide. Haematologica, 2012, Volume: 97, Issue:2 Topics: Adult; Aged; Female; Humans; Lenalidomide; Male; Middle Aged; Nervous System Diseases; POEMS Syndrome; Recovery of Function; Thalidomide; Treatment Outcome	2012
Tumoral Bing-Neel Syndrome presenting as a cerebellar mass. Clinical neurology and neurosurgery, 2013, Volume: 115, Issue:6 Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Brain Edema; Cerebellar Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Fatal Outcome; Humans; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Nervous System Diseases; Neurosurgical Procedures; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia	2013